Cancer is a complex disease driven by somatic mutations accumulating within the genome.  Advances in next-generation sequencing (NGS) have revolutionized our understanding of the genetic landscape of various cancers, revealing a heterogeneous collection of driver mutations and genomic alterations specific to individual tumors. This intricate genetic heterogeneity underpins the growing field of personalized medicine in oncology.  Identification of actionable mutations, through techniques such as whole-exome sequencing and RNA sequencing, allows for targeted therapies matched to specific genetic profiles.  For instance, the presence of EGFR mutations in lung adenocarcinoma predicts responsiveness to EGFR tyrosine kinase inhibitors.  Furthermore,  immunotherapy approaches, such as checkpoint inhibitors, have demonstrated remarkable efficacy in cancers with high mutational burden, highlighting the importance of understanding the tumor's immunogenic landscape.  However, challenges remain, including the identification of biomarkers for treatment response prediction and the management of acquired resistance.  Ongoing research focuses on integrating multi-omics data, including genomics, transcriptomics, and proteomics, to refine personalized therapeutic strategies and improve patient outcomes. Ultimately, a deeper understanding of the genetic basis of cancer is crucial for developing truly effective personalized cancer therapies.